Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951091 | 0.87 | GAA (0.60) | MAPTCYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL27823612 | 0.86 | MAPT (0.67) | MAPTCYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL4862020 | 0.85 | MAPT (0.65) | MAPTCYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL11121780 | 0.83 | MAPT (0.62) | MAPTCYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL9468482 | 0.83 | MAPT (0.62) | MAPTCYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL27823621 | 0.83 | MAPT (0.62) | MAPTCYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL4805587 | 0.82 | MAPT (0.60) | MAPTCYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL5992633 | 0.82 | KMT2A (0.53) | MAPTHTTHSD17B10GAAALDH1A1 | |
| SCHEMBL8373327 | 0.81 | MAPT (1.00) | MAPTCYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL9752202 | 0.81 | CYP1A2 (0.59) | MAPTCYP1A2CYP3A4CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101058558-A | 4-Oxy-1(4H)-quinoline carboxylic acids compound and composition with aldose reductase inhibition activity and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL (CN) | 2007-10-24 | — | — | CN | claimed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| CN-104350106-B | Comprise the laundry care composition of dyestuff | 宝洁公司 | 2017-03-08 | — | — | CN | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1885695-B1 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-5520883-A | OPTICAL DETECTION WITH CARRIER MATRIX AND GLUCOSE BORONATE | MILES INC. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0316762-B1 | TEST DEVICES FOR DETERMINATION OF OCCULT BLOOD AND GLUCOSE | MILES INC. (US) | 1992-04-22 | — | — | EP | disclosed |
| US-4895798-A | GLUCOSE OXIDATES, GLUCOSE DERIVATIVE | MILES, INC. (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0316762-A1 | Test devices for determination of occult blood and glucose | MILES INC. (US) | 1989-05-24 | — | — | EP | disclosed |
| EP-0140337-B1 | MULTIZONE ELEMENT AND METHOD FOR ANALYSIS OF WHOLE BLOOD | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1989-04-19 | — | — | EP | disclosed |
| US-H600-H | SPECTROPHOTOMETRY | FUJI PHOTO FILM CO., LTD. (JP) | 1989-03-07 | — | — | US | disclosed |
| US-4637978-A | MULTIZONAL, SPECTROPHOTOMETRY, COLORS/MATERIALS; SPREADING, POROSITY | EASTMAN KODAK COMPANY (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0140337-A2 | Multizone element and method for analysis of whole blood | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-05-08 | — | — | EP | disclosed |
| US-4508902-A | OXIDATION OF 1,2,3,4-TETRAHYDROQUINOLINE-4-ONES | RHONE-POULENC SANTE (FR) | 1985-04-02 | — | — | US | disclosed |
| US-4412075-A | Process for the preparation of quinolin-4-ones | RHONE-POULENC SANTE (FR) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | MAPT 2499/4885CYP1A2 3833/4885CYP3A4 4513/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | MAPT 2324/4885CYP1A2 3980/4885CYP3A4 4084/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | MAPT 2212/4885CYP1A2 3658/4885CYP3A4 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.